Grace Therapeutics, Inc.
GRCE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001444192
In the last 90 days, Grace Therapeutics, Inc. insiders filed 5 open-market purchases and 0 sales; 33 institutions reported holding it in 13F filings for Q2 2026, worth $8.74M in total; no superinvestor holds it.
Q1 2026 vs. Q4 2025
How the institutions holding Grace Therapeutics, Inc. changed between Q4 2025 and Q1 2026.
All holders in Q1 2026All holders in Q4 2025
| Measure | Q4 2025 | Of which not filed for Q1 2026 | Q1 2026 | Change |
|---|---|---|---|---|
| Holders | 23 | 2 | 34 | +13 |
| Shares | 4.33M | 424.0K | 4.26M | +360.8K (+9.2%) |
| Value | $15.0M | $1.48M | $19.7M | +$6.23M (+46.1%) |
2 institutions that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (18)
Institutions that held Grace Therapeutics, Inc. at the end of Q1 2026 but not at the end of Q4 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Eversept Partners, LP | 756,600 | $3.50M | 0.23% |
| Vanguard Capital Management LLC | 401,656 | $1.86M | 0.00% |
| Jane Street Group, LLC | 167,097 | $773.7K | 0.00% |
| Marshall Wace, LLP | 91,416 | $423.3K | 0.00% |
| Connective Capital Management, LLC | 84,549 | $391.5K | 0.32% |
| Quadrature Capital Ltd | 66,822 | $309.4K | 0.00% |
| Birchview Capital, LP | 50,000 | $231.5K | 0.13% |
| Diametric Capital, LP | 39,796 | $184.3K | 0.05% |
| Pale Fire Capital SE | 37,762 | $174.8K | 0.02% |
| UBS Group AG | 26,301 | $121.8K | 0.00% |
| Kestra Private Wealth Services, LLC | 13,000 | $60.2K | 0.00% |
| Prelude Capital Management, LLC | 10,074 | $46.6K | 0.00% |
| Oppenheimer & Co Inc | 10,000 | $46.3K | 0.00% |
| Vanguard Fiduciary Trust Co | 8,750 | $40.5K | 0.00% |
| Group One Trading, L.P. | 5,000 | $23.1K | 0.00% |
| Wells Fargo & Company | 1,800 | $8.33K | 0.00% |
| SRS Capital Advisors, Inc. | 500 | $2.31K | 0.00% |
| Caitong International Asset Management Co., Ltd | 82 | $380 | 0.00% |
Sold out (5)
Institutions that held Grace Therapeutics, Inc. at the end of Q4 2025 and filed for Q1 2026 without it.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| AIGH Capital Management LLC | 907,217 | $3.15M |
| ADAR1 Capital Management, LLC | 641,988 | $2.22M |
| Gsa Capital Partners LLP | 13,774 | $48.0K |
| Stratos Wealth Partners, LTD. | 11,182 | $38.7K |
| Flagship Harbor Advisors, LLC | 2 | $7 |
Not filed for Q1 2026 yet (2)
Institutions that held Grace Therapeutics, Inc. at the end of Q4 2025 and haven't filed a 13F for Q1 2026. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Vanguard Group Inc | 423,981 | $1.48M |
| Motiv8 Investments LLC | 20 | $0 |